Insider Selling: CeriBell (NASDAQ:CBLL) VP Sells $23,851.86 in Stock

CeriBell, Inc. (NASDAQ:CBLL) VP David Foehr sold 993 shares of the firm’s stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $24.02, for a total value of $23,851.86. Following the sale, the vice president owned 36,758 shares of the company’s stock, valued at $882,927.16. The trade was a 2.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

David Foehr also recently made the following trade(s):

• On Monday, August 24th, David Foehr sold 859 shares of CeriBell stock. The shares were sold at an average price of $23.95, for a total value of $20,573.05.

CeriBell Stock Performance

Shares of CBLL opened at $23.37 on Friday. The company has a market capitalization of $896.94 million, a PE ratio of -13.28 and a beta of 0.81. The company has a debt-to-equity ratio of 0.16, a quick ratio of 8.79 and a current ratio of 9.18. The company’s 50 day moving average price is $20.00 and its 200 day moving average price is $19.32. CeriBell, Inc. has a 52 week low of $10.85 and a 52 week high of $25.33.

CeriBell (NASDAQ:CBLL) last released its earnings results on Monday, August 10th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.04). The company had revenue of $28.10 million during the quarter, compared to analysts’ expectations of $27.28 million. CeriBell had a negative return on equity of 44.85% and a negative net margin of 64.73%. Research analysts expect that CeriBell, Inc. will post -1.96 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts recently issued reports on the company. Barclays raised CeriBell to a “neutral” rating in a research report on Tuesday, August 18th. BTIG Research raised their price target on CeriBell from $28.00 to $30.00 and gave the stock a “buy” rating in a research note on Tuesday, August 18th. Weiss Ratings upgraded CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 13th. Finally, Canaccord Genuity Group boosted their price target on CeriBell from $25.00 to $26.00 and gave the company a “buy” rating in a research note on Tuesday, August 11th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $22.40.

Hedge Funds Weigh In On CeriBell

Several hedge funds have recently bought and sold shares of the business. BlackRock Inc. acquired a new stake in shares of CeriBell in the second quarter worth about $37,657,000. Vanguard Group Inc. increased its holdings in shares of CeriBell by 11.1% during the 3rd quarter. Vanguard Group Inc. now owns 1,473,856 shares of the company’s stock valued at $16,935,000 after acquiring an additional 147,013 shares during the last quarter. KCM Capital Inc raised its stake in shares of CeriBell by 40.0% in the 1st quarter. KCM Capital Inc now owns 1,400,000 shares of the company’s stock valued at $25,662,000 after acquiring an additional 400,000 shares in the last quarter. Yu Fan raised its stake in shares of CeriBell by 10.7% in the 2nd quarter. Yu Fan now owns 1,353,166 shares of the company’s stock valued at $25,345,000 after acquiring an additional 130,964 shares in the last quarter. Finally, Bank of New York Mellon Corp lifted its holdings in CeriBell by 1,945.9% in the 4th quarter. Bank of New York Mellon Corp now owns 1,221,927 shares of the company’s stock worth $26,797,000 after purchasing an additional 1,162,200 shares during the last quarter.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.